J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
1. Johnson & Johnson considers acquiring Intra-Cellular Therapies, impacting ITCI's valuation. 2. Potential acquisition indicates strategic interest in ITCI's biopharmaceutical assets.